Clinical trial
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
NCT06383273 is registered in ClinicalTrials.gov with Melt Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
- Lead sponsor
- Melt Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- May 1, 2024
- Completion date
- January 31, 2025
- Enrollment
- 528 (estimated)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.